mulpleo (previously lusutrombopag shionogi)
shionogi b.v. - lusutrombopag - trombocitopenia - antihemorrágicos - mulpleo está indicado para el tratamiento de la trombocitopenia severa en pacientes adultos con enfermedad hepática crónica sometidos a procedimientos invasivos.
eltrombopag 25 mg
laboratorios biogenet scc ecuador - eltrombopag 25,0 mg - tableta recubierta - eltrombopag olamina 31,9 mg (equivalente a 25,0 mg de eltrombopag)
eltrombopag comprimidos recubiertos 25 mg
seven pharma chile s.p.a. - eltrombopag olamina - sin formulas
revolade comprimidos recubiertos 12,5 mg (eltrombopag)
novartis chile s.a. - eltrombopag - sin formulas
eltrombopag 50 mg
laboratorios biogenet scc ecuador - eltrombopag 50,0 mg - tableta recubierta - cada tableta recubierta contiene: eltrombopag olamina 63,8 mg (equivalente a 50,0 mg de eltrombopag)
eltrombopag 50mg tabletas recubiertas
remus pharmaceuticals ltd. india - eltrombopag 50mg - tableta recubierta - cada tableta recubierta contiene: eltrombopag olamine 63.8 mg equivalente a 50 mg de eltrombopag ácido libre
eltrombopag 25mg tabletas recubiertas
remus pharmaceuticals ltd. india - eltrombopag 25mg - tableta recubierta - cada tableta recubierta contiene: eltrombopag olamine 31.9 mg equivalente a 25 mg de eltrombopag ácido libre
doptelet
swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenia - antihemorrágicos - doptelet está indicado para el tratamiento de la trombocitopenia severa en pacientes adultos con enfermedad hepática crónica que está programado para someterse a un procedimiento invasivo. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. corticosteroides, inmunoglobulinas).
revolade
novartis europharm limited - eltrombopag - púrpura, trombocitopénica, idiopática - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 y 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 y 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
revolade comprimidos recubiertos 25 mg (eltrombopag)
novartis chile s.a. - eltrombopag - sin formulas